Final rule for pain reliever labels
This article was originally published in The Tan Sheet
Executive Summary
FDA has prepared a final rule to require that acetaminophen-containing and non-steroidal anti-inflammatory OTC drugs carry updated warnings on adverse gastrointestinal and hepatic side effects linked to improper use. The 1rule slated for publication in the Jan. 26 Federal Register amends FDA's labeling regulations and the tentative final monograph on nonprescription internal analgesic, anti-pyretic and anti-rheumatic drug products. The compliance deadline is one year from the date of publication. FDA's December 2006 proposed rule raised industry concerns that more flexibility was needed and that some of the changes were not supported by science (2"The Tan Sheet" June 11, 2007, p. 3). While some of the Consumer Healthcare Products Association's comments were not adopted for the rule, the trade group said Jan. 23 that its members already voluntarily have implemented "many of these label changes," including highlighting the active ingredient
You may also be interested in...
Pain relievers label final rule not ready
FDA says it "inadvertently, mistakenly posted" a Jan. 23 pre-publication notice indicating that a final rule for OTC internal analgesic product labels would be published in the Jan. 26 Federal Register. The rule would amend labels for non-steroidal anti-inflammatory drugs and acetaminophen-containing products to include warnings of gastrointestinal and liver injuries associated with improper use (1"The Tan Sheet" Jan. 26, 2009, In Brief). FDA announced the posting error Jan. 26, but did not say when the rule will be published
Proposed OTC Acetaminophen Warnings Not Supported By Science – McNeil
Existing science on the safety and efficacy of OTC acetaminophen does not substantiate several FDA-proposed warnings to be included in labeling for the analgesic, McNeil Consumer Healthcare asserts
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.